Announced details
Treatment of glioblastoma (GBM)
6 patients in the expanded cohort; median overall survival (OS) of 19.9 months
Based on 6 patients in the expanded cohort
We have entered into an exclusive negotiation agreement with TME Pharma A.G. for the worldwide rights to NOX-A12.
TME Pharma A.G. is the company with which we have entered into an exclusive negotiation agreement for the worldwide rights to NOX-A12, and TME Pharma N.V. is its parent company. Other information, including location, representative, capital, and year established, is not disclosed.
2026 German University Medicine Award (Preis der Deutschen Hochschulmedizin 2026)
Association of Medical Faculties in Germany (MFT) and Association of German University Hospitals (VUD)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Published in the academic journal Nature Communications in 2024 and 2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | NOX-A12, GLORIA |
| Counterparty | TME Pharma N.V., TME Pharma A.G. |
| Counterparty overview | TME Pharma A.G. is the company with which we have entered into an exclusive negotiation agreement for the worldwide rights to NOX-A12, and TME Pharma N.V. is its parent company. Other information, including location, representative, capital, and year established, is not disclosed. |
| Relationship with the Company | We have entered into an exclusive negotiation agreement with TME Pharma A.G. for the worldwide rights to NOX-A12. |
| Applicable area | Treatment of glioblastoma (GBM) |
| Award/certification name | 2026 German University Medicine Award (Preis der Deutschen Hochschulmedizin 2026) |
| Awarding / certifying body | Association of Medical Faculties in Germany (MFT) and Association of German University Hospitals (VUD) |
| Quantitative Effects | 6 patients in the expanded cohort; median overall survival (OS) of 19.9 months |
| Usage history | Based on 6 patients in the expanded cohort |
| Source | Published in the academic journal Nature Communications in 2024 and 2026 |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Association of Medical Faculties in Germany (MFT) and the Association of German University Hospitals (VUD) recognized the team's innovation in university medical research and its contribution to clinical applications.